On the discovered Cancer Driving Nucleotides (CDNs)-Distributions across genes, cancer types and patients (Updated September 23, 2024).

A recent preprint abstract discusses the identification of cancer driving mutations, specifically point mutations known as Cancer Driving Nucleotides (CDNs). The study reveals that CDNs tend to code for amino acids with diverse chemical properties and are more likely to be found on non-canonical cancer driving genes. CDNs are also more widely shared among different types of cancer due to their high resolution at the nucleotide level. The study suggests that expanding the sample size can lead to the identification of most CDNs, which could aid in the development of targeted therapies. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)